M&A, Recapitalization, and Growth Financing Advice to Drive Transformative Transactions

Crosstree serves as your vested partner to empower you — a founder, investor, or operator — to confidently connect with leading health science companies, align interests, and optimize outcomes. We work within the pharma services, diagnostics and tools, and digital health sectors to help our clients explore greater market insights and financial possibilities by providing objective insight to deliver the best possible outcome for you. Get expert advice for your mergers and acquisitions, recapitalizations, or growth financings.

Our Results

SUPERIOR OUTCOMES ARE OUR STANDARD

90%

Success Rate

85%

Strategic Buyers

35%

Cross-border

Crosstree’s Client Outcomes Consistently Exceed Industry Benchmarks

Crosstree’s deep industry focus fosters efficient project execution. The company’s relationships with investors and strategic buyers are unmatched in the industry.

Crosstree’s deals consistently achieve “spike valuations” through concise articulation of client value propositions, credible financial and technical support, and thoughtful alignment of industry trends.

Crosstree’s culmination of industry expertise that leverages market data, trends, and a high-profile network, drives an outstanding closing rate of almost 90%.

By combining technology, structured project management methodology, and a focused process approach, Crosstree closes transactions faster — with less resourcing strain on clients — compared to traditional investment banks.

Recent Deals

DataCeutics has been acquired by Navitas Life Sciences, a TAKE Solutions Company
MolecularMD has been acquired by ICON Plc.
Velos acquired by WCG, a portfolio company of Arsenal Capital Partners
GSK Sold Assets to Crown Laboratories